Lu AA24493 is in clinical phase II in the treatment of Friedreich's ataxia and
in clinical phase I in the treatment of acute ischaemic stroke. Ongoing studies
in both programmes are expected to be concluded in the second half of 2010.
Saturday, August 14, 2010
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment